Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

ACTIVE_NOT_RECRUITING

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Lead Sponsor:

Janssen Research & Development, LLC

Conditions:

Plaque Psoriasis

Eligibility:

All Genders

12+ years

Phase:

PHASE3

Brief Summary

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Eligibility Criteria

Inclusion

  • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
  • Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
  • Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
  • Total investigator global assessment (IGA) \>=3 at screening and baseline
  • Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion

  • Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)
  • Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
  • Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
  • Transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)

Key Trial Info

Start Date :

April 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 20 2027

Estimated Enrollment :

752 Patients enrolled

Trial Details

Trial ID

NCT06934226

Start Date

April 15 2025

End Date

August 20 2027

Last Update

December 5 2025

Active Locations (160)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 40 (160 locations)

1

Cahaba Research Inc

Birmingham, Alabama, United States, 35244

2

California Dermatology & Clinical Research Institute

Encinitas, California, United States, 92024

3

T Joseph Raoof Md Inc

Encino, California, United States, 91436

4

First OC Dermatology

Fountain Valley, California, United States, 92708